If a combination therapy of anti-VEGF antibody and edaravone exerts a great inhibitory effect against CNV, edaravone would be a powerful candidate for AMD therapeutic medicine and could extend the period of intravitreal injection. Here, VEGFA is linked to age-related macular degeneration.